SCHEMBL14675019

SCHEMBL14675019

C=C(C)C(=O)OC(COP(=O)([O-])OCC[N+](C)(C)C)CC(=C)C(=O)OCCCC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1D P25100 1/20 0.55
PTAFR P25105 1/20 0.55
HTR1D P28221 1/20 0.55
HTR2C P28335 1/20 0.55
ADRA1B P35368 1/20 0.55
DRD3 P35462 1/20 0.55
TMEM97 Q5BJF2 1/20 0.55
MAPT P10636 3/20 0.54
SMN1; SMN2 Q16637 2/20 0.53
NR5A2 O00482 1/20 0.53
NR5A1 Q13285 1/20 0.53
MAPK1 P28482 5/20 0.49
MEN1 O00255 3/20 0.49
GMNN O75496 3/20 0.49
LMNA P02545 3/20 0.49
BLM P54132 3/20 0.49
KMT2A Q03164 3/20 0.49
NPSR1 Q6W5P4 3/20 0.49
PRKD3 O94806 1/20 0.49
PRKCG P05129 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3655243 0.96 ADRA1D (0.61) ADRA1DPTAFRHTR1DHTR2CADRA1B
SCHEMBL1260833 0.85 ADRA1D (0.61) ADRA1DPTAFRHTR1DHTR2CADRA1B
SCHEMBL1260814 0.83 ADRA1D (0.57) ADRA1DPTAFRHTR1DHTR2CADRA1B
SCHEMBL1260662 0.83 ADRA1D (0.57) ADRA1DPTAFRHTR1DHTR2CADRA1B
SCHEMBL368310 0.81 LMNA (0.56) ADRA1DPTAFRHTR1DHTR2CADRA1B
SCHEMBL6235107 0.78 TSHR (0.54) LMNAPRKCAPRKCEPRKCQPRKCD
SCHEMBL9067446 0.78 ADRA1D (0.62) ADRA1DPTAFRHTR1DHTR2CADRA1B
SCHEMBL14990456 0.77 LMNA (0.64) ADRA1DPTAFRHTR1DHTR2CADRA1B
SCHEMBL3923049 0.77 LMNA (0.64) ADRA1DPTAFRHTR1DHTR2CADRA1B
SCHEMBL423161 0.77 LMNA (0.57) ADRA1DPTAFRHTR1DHTR2CADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130034509-A1 COSMETIC TREATMENT METHOD INVOLVING A COMPOUND CAPABLE OF CONDENSING IN SITU L'OREAL (FR) 2013-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130034509-A1 COSMETIC TREATMENT METHOD INVOLVING A COMPOUND CAPABLE OF CONDENSING IN SITU POLR1C, CUTA, MITF ADRA1D 4768/4885PTAFR 4388/4885HTR1D 4188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.